Title:Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Volume: 16
Issue: 14
Author(s): Mónica P. A. Ferreira, Vimalkumar Balasubramanian, Jouni Hirvonen, Heikki Ruskoaho and Hélder A. Santos
Affiliation:
关键词:
心脏生物标志物，心血管疾病，成像，心肌梗死，纳米药物，纳米颗粒。
摘要: Nanotechnology has impacted tremendously the medical research with increasing importance
in the development of new therapeutic approaches and applications. Among these applications,
the use of nanocarriers has gained particular interest in order to achieve successful delivery of therapeutics
and imaging agents for the treatment and diagnostics of different diseases, such as cancer, infections,
diabetes, lung, brain and cardiovascular diseases. Heart failure (HF) is a complex clinical
syndrome derived from multiple causes that arise from secondary to inherited or acquired abnormalities
of cardiac structure and/or function. Myocardial infarction (MI), the major cause of HF, continues to be an increasing
problem in terms of morbidity, mortality and healthcare costs worldwide. Currently, established pharmacological drugs
have proven to be effective in reducing hypertrophy, remodeling of the myocardium, and in reducing morbidity and mortality
in patients with HF. However, despite optimal treatment with existing drugs, the prognosis of HF is poor and also
the possible deleterious effects of therapeutic agents must be considered when used at doses required for the desired
therapeutic effect. Therefore, novel therapeutic strategies are urgently needed to prevent high morbidity and mortality associated
with MI and HF. In this review, we will present recent developments in nanomedicine research envisaged to have
an important impact on the treatment of cardiovascular diseases, particularly MI. In addition, we will discuss the use of
different advanced modified nanosystems for molecular imaging and therapeutics of MI, presenting several in vitro and in
vivo examples. Finally, we will conclude with an overview of the potential of nanomedicines in the future for the treatment
of cardiovascular diseases.
48
4